Samsung Biologics America signed a definitive agreement to acquire Human Genome Sciences’ Rockville, Maryland biologics manufacturing site from GSK for $280 million, with closing expected near the end of Q1 2026. The deal secures Samsung Biologics’ first U.S. manufacturing foothold, adding two cGMP plants and roughly 60,000 L of capacity and retaining more than 500 employees to maintain continuity. Samsung said it will invest further to expand capacity and upgrade technologies to support clinical and commercial biologics production across modalities including mAbs, ADCs and mRNA. Samsung CEO John Rim framed the purchase as a strategic step to strengthen U.S. supply‑chain resilience and to support next‑generation therapies. For contract development and manufacturing (CDMO) markets, the acquisition signals continued vertical expansion by Asian CDMOs into U.S. assets and underscores industry demand for geographically diversified biologics capacity ahead of anticipated pipeline commercialization.